Administration, Intravesical

"Administration, Intravesical" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

The instillation or other administration of drugs into the bladder, usually to treat local disease, including neoplasms.

Descriptor ID	D000283
MeSH Number(s)	E02.319.267.120.505
Concept/Terms	Administration, Intravesical Administration, Intravesical Intravesical Drug Administration Drug Administration, Bladder Administration, Intravesical Drug Administrations, Intravesical Drug Drug Administration, Intravesical Drug Administrations, Intravesical Intravesical Drug Administrations Intravesical Administration Administrations, Intravesical Intravesical Administrations Bladder Drug Administration Administration, Bladder Drug Administrations, Bladder Drug Bladder Drug Administrations Drug Administrations, Bladder Instillation, Bladder Instillation, Bladder Bladder Instillation Bladder Instillations Instillations, Bladder Intravesical Instillation Instillation, Intravesical Instillations, Intravesical Intravesical Instillations Intravesical Injection Intravesical Injection Injections, Intravesical Injection, Intravesical Intravesical Injections

Below are MeSH descriptors whose meaning is more general than "Administration, Intravesical".

Analytical, Diagnostic and Therapeutic Techniques and Equipment [E]
Therapeutics [E02]
Drug Therapy [E02.319]
Drug Administration Routes [E02.319.267]
Administration, Topical [E02.319.267.120]
Administration, Intravesical [E02.319.267.120.505]

Below are MeSH descriptors whose meaning is related to "Administration, Intravesical".

Below are MeSH descriptors whose meaning is more specific than "Administration, Intravesical".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Administration, Intravesical" by people in this website by year, and whether "Administration, Intravesical" was a major or minor topic of these publications.

Bar chart showing 12 publications over 9 distinct years, with a maximum of 2 publications in 2011 and 2017 and 2022

To see the data from this visualization as text, click here.

Year	Minor Topic	Total
1998	1	1
2003	1	1
2008	1	1
2009	1	1
2011	2	2
2017	2	2
2019	1	1
2022	2	2
2024	1	1

Below are the most recent publications written about "Administration, Intravesical" by people in Profiles.

Narayan VM, Boorjian SA, Alemozaffar M, Konety BR, Shore ND, Gomella LG, Kamat AM, Bivalacqua TJ, Montgomery JS, Lerner SP, Busby JE, Poch M, Crispen PL, Steinberg GD, Schuckman AK, Downs TM, Mashni J, Lane BR, Guzzo TJ, Bratslavsky G, Karsh LI, Woods ME, Brown G, Canter D, Luchey A, Lotan Y, Inman BA, Williams MB, Cookson MS, Chang SS, Sankin AI, O'Donnell MA, Sawutz D, Philipson R, Parker NR, Yla-Herttuala S, Rehm D, Jakobsen JS, Juul K, Dinney CPN. Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Gu?rin-Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial. J Urol. 2024 Jul; 212(1):74-86.

View in: PubMed
D'Amico MJ, Foss H, Uhr A, Rudnick B, Kloniecke E, Gomella LG. Hemorrhagic cystitis: a review of the literature and treatment options. Can J Urol. 2022 10; 29(5):11276-11283.

View in: PubMed
Flaig TW, Spiess PE, Abern M, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Chan K, Chang S, Friedlander T, Greenberg RE, Guru KA, Herr HW, Hoffman-Censits J, Kishan A, Kundu S, Lele SM, Mamtani R, Margulis V, Mian OY, Michalski J, Montgomery JS, Nandagopal L, Pagliaro LC, Parikh M, Patterson A, Plimack ER, Pohar KS, Preston MA, Richards K, Sexton WJ, Siefker-Radtke AO, Tollefson M, Tward J, Wright JL, Dwyer MA, Cassara CJ, Gurski LA. NCCN Guidelines? Insights: Bladder Cancer, Version 2.2022. J Natl Compr Canc Netw. 2022 08; 20(8):866-878.

View in: PubMed
Huggins A, Adam M, Ehmann D, Eagle RC, Malloy B, Garg SJ. A CASE OF INTRAVESICAL BACILLUS CALMETTE-GUERIN-RELATED ENDOPHTHALMITIS AND RETINITIS CONFIRMED WITH RETINAL BIOPSY. Retin Cases Brief Rep. 2019; 13(4):333-336.

View in: PubMed
Shore ND, Boorjian SA, Canter DJ, Ogan K, Karsh LI, Downs TM, Gomella LG, Kamat AM, Lotan Y, Svatek RS, Bivalacqua TJ, Grubb RL, Krupski TL, Lerner SP, Woods ME, Inman BA, Milowsky MI, Boyd A, Treasure FP, Gregory G, Sawutz DG, Yla-Herttuala S, Parker NR, Dinney CPN. Intravesical rAd-IFNa/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin-Refractory or Relapsed Non-Muscle-Invasive Bladder Cancer: A Phase II Randomized Study. J Clin Oncol. 2017 Oct 20; 35(30):3410-3416.

View in: PubMed
Iyer S, Lotsof E, Zhou Y, Tran A, Botros C, Sand P, Goldberg R, Tomezsko J, Gafni-Kane A, Botros S. Which bladder instillations are more effective? DMSO vs. bupivacaine/heparin/triamcinolone: a retrospective study. Int Urogynecol J. 2017 Sep; 28(9):1335-1340.

View in: PubMed
Wosnitzer MS, Domingo-Domenech J, Castillo-Martin M, Ritch C, Mansukhani M, Petrylack DP, Benson MC, McKiernan JM, Cordon-Cardo C. Predictive value of microtubule associated proteins tau and stathmin in patients with nonmuscle invasive bladder cancer receiving adjuvant intravesical taxane therapy. J Urol. 2011 Nov; 186(5):2094-100.

View in: PubMed
McKiernan JM, Barlow LJ, Laudano MA, Mann MJ, Petrylak DP, Benson MC. A phase I trial of intravesical nanoparticle albumin-bound paclitaxel in the treatment of bacillus Calmette-Guérin refractory nonmuscle invasive bladder cancer. J Urol. 2011 Aug; 186(2):448-51.

View in: PubMed
Laudano MA, Barlow LJ, Murphy AM, Petrylak DP, Desai M, Benson MC, McKiernan JM. Long-term clinical outcomes of a phase I trial of intravesical docetaxel in the management of non-muscle-invasive bladder cancer refractory to standard intravesical therapy. Urology. 2010 Jan; 75(1):134-7.

View in: PubMed
Sabichi AL, Lerner SP, Atkinson EN, Grossman HB, Caraway NP, Dinney CP, Penson DF, Matin S, Kamat A, Pisters LL, Lin DW, Katz RL, Brenner DE, Hemstreet GP, Wargo M, Bleyer A, Sanders WH, Clifford JL, Parnes HL, Lippman SM. Phase III prevention trial of fenretinide in patients with resected non-muscle-invasive bladder cancer. Clin Cancer Res. 2008 Jan 01; 14(1):224-9.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement